SCHEMBL10293237

SCHEMBL10293237

CCNC1CCCCC1C

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
FUCA1 P04066 1/20 0.43
EPHX1 P07099 1/20 0.39
TSHR P16473 2/20 0.39
NPSR1 Q6W5P4 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.38
USP2 O75604 1/20 0.38
ALDH1A1 P00352 5/20 0.35
TAS1R3 Q7RTX0 4/20 0.35
TAS1R1 Q7RTX1 4/20 0.35
KDM4E B2RXH2 3/20 0.35
GAA P10253 2/20 0.35
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
CA4 P22748 1/20 0.35
TAS1R2 Q8TE23 1/20 0.34
POLB P06746 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
HTT P42858 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10151647 1.00 FUCA1 (0.43) FUCA1EPHX1TSHRNPSR1SMN1; SMN2
SCHEMBL10151965 1.00 FUCA1 (0.43) FUCA1EPHX1TSHRNPSR1SMN1; SMN2
SCHEMBL10069387 1.00 FUCA1 (0.43) FUCA1EPHX1TSHRNPSR1SMN1; SMN2
SCHEMBL19817617 0.98 EPHX1 (0.42) FUCA1EPHX1TSHRNPSR1SMN1; SMN2
SCHEMBL21232876 0.98 EPHX1 (0.42) FUCA1EPHX1TSHRNPSR1SMN1; SMN2
SCHEMBL22170610 0.95
Alcohol SCHEMBL14109089 0.93 FUCA1 (0.44) FUCA1EPHX1TSHRNPSR1SMN1; SMN2
Alcohol SCHEMBL14109615 0.91 EPHX1 (0.43) FUCA1EPHX1TSHRNPSR1SMN1; SMN2
Alcohol SCHEMBL14109452 0.91 EPHX1 (0.43) FUCA1EPHX1TSHRNPSR1SMN1; SMN2
Propanol SCHEMBL14109491 0.89 FUCA1 (0.41) FUCA1EPHX1TSHRNPSR1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12559453-B2 Sulfonic acid-modified polyisocyanate and preparation method therefor WANHUA CHEMICAL GROUP CO., LTD. (CN) 2026-02-24 US claimed
EP-4144780-B1 SULFONIC ACID-MODIFIED POLYISOCYANATE AND PREPARATION METHOD THEREFOR WANHUA CHEMICAL GROUP CO LTD (CN) 2025-12-24 EP claimed
US-20230257344-A1 SULFONIC ACID-MODIFIED POLYISOCYANATE AND PREPARATION METHOD THEREFOR WANHUA CHEMICAL GROUP CO., LTD. (CN) 2023-08-17 US claimed
EP-4144780-A1 SULFONIC ACID-MODIFIED POLYISOCYANATE AND PREPARATION METHOD THEREFOR Wanhua Chemical Group Co., Ltd. (CN) 2023-03-08 EP claimed
WO-2022257585-A1 SULFONIC ACID-MODIFIED POLYISOCYANATE AND PREPARATION METHOD THEREFOR 万华化学集团股份有限公司 2022-12-15 WO claimed
CN-115466201-A Sulfonic acid modified polyisocyanate and preparation method thereof 万华化学集团股份有限公司 2022-12-13 CN claimed
EP-4144780-B1 SULFONIC ACID-MODIFIED POLYISOCYANATE AND PREPARATION METHOD THEREFOR WANHUA CHEMICAL GROUP CO LTD (CN) 2025-12-24 EP disclosed
US-11655371-B2 Color material dispersion liquid, color resin composition, color filter, liquid crystal display device, and light-emitting display device DAI NIPPON PRINTING CO., LTD. (JP) 2023-05-23 US disclosed
EP-4144780-A1 SULFONIC ACID-MODIFIED POLYISOCYANATE AND PREPARATION METHOD THEREFOR Wanhua Chemical Group Co., Ltd. (CN) 2023-03-08 EP disclosed
WO-2022257585-A1 SULFONIC ACID-MODIFIED POLYISOCYANATE AND PREPARATION METHOD THEREFOR 万华化学集团股份有限公司 2022-12-15 WO disclosed
CN-115466201-A Sulfonic acid modified polyisocyanate and preparation method thereof 万华化学集团股份有限公司 2022-12-13 CN disclosed
CN-109415298-B Compounds and intermediates thereof 大日本印刷株式会社 2022-03-29 CN disclosed
US-20210324200-A1 COLOR MATERIAL DISPERSION LIQUID, COLOR RESIN COMPOSITION, COLOR FILTER, LIQUID CRYSTAL DISPLAY DEVICE, AND LIGHT-EMITTING DISPLAY DEVICE DAI NIPPON PRINTING CO., LTD. (JP) 2021-10-21 US disclosed
US-10640456-B2 Compound and intermediate thereof DAI NIPPON PRINTING CO., LTD. (JP) 2020-05-05 US disclosed
US-20190308931-A1 COMPOUND AND INTERMEDIATE THEREOF DAI NIPPON PRINTING CO., LTD. (JP) 2019-10-10 US disclosed
US-20190218200-A1 POTASSIUM CHANNEL MODULATORS NOVARTIS AG (CH) 2019-07-18 US disclosed
US-8211935-B2 Heterocyclic derivatives for modulation of calcium channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-07-03 US disclosed
US-20110178061-A1 HETEROCYCLIC DERIVATIVES FOR MODULATION OF CALCIUM CHANNELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-07-21 US disclosed
US-20110015173-A1 PYRROLOPYRIDINE INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2011-01-20 US disclosed
US-7569604-B2 Heterocyclic derivatives for modulation of calcium channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-08-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190308931-A1 COMPOUND AND INTERMEDIATE THEREOF AHR, ARNT, NR1H2 FUCA1 4487/4885EPHX1 1445/4885TSHR 2157/4885
US-20230257344-A1 SULFONIC ACID-MODIFIED POLYISOCYANATE AND PREPARATION METHOD THEREFOR TST, SULT1A1, SULT2A1 FUCA1 1788/4885EPHX1 4414/4885TSHR 3601/4885
US-20190218200-A1 POTASSIUM CHANNEL MODULATORS KCNJ11, KCNJ2, KCNJ1 FUCA1 2256/4885EPHX1 2639/4885TSHR 2599/4885
US-20110015173-A1 PYRROLOPYRIDINE INHIBITORS OF KINASES CDC7, MAP3K7, CDK1 FUCA1 4060/4885EPHX1 3143/4885TSHR 3466/4885
US-12559453-B2 Sulfonic acid-modified polyisocyanate and preparation method therefor TMT1A, SRMS, FTO FUCA1 3418/4885EPHX1 4673/4885TSHR 1100/4885
US-20110178061-A1 HETEROCYCLIC DERIVATIVES FOR MODULATION OF CALCIUM CHANNELS CACNA1D, ORAI1, CACNA1C FUCA1 4810/4885EPHX1 2430/4885TSHR 4200/4885
US-10640456-B2 Compound and intermediate thereof AHR, ARNT, NR1H2 FUCA1 4487/4885EPHX1 1445/4885TSHR 2157/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.